Prescriptions Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA’s 2024 Update
In the past year, the growth of prescription drug utilization and spending has much to do with the use of GLP-1 agonists to treat diabetes and obesity, along with immunology therapy, and lipid meds, along with specialty medicines now accounting for over half of spending — up from 49% in 2018. This update comes from The Use of Medicines in the U.S. 2024 from the IQVIA Institute for Human Data Science. The annual report details trends in health services utilization, the use of prescription drugs, patient financing of those costs, the drivers underpinning the medicines spending, and an outlook to 2028.
Hims and Hers and Hearts – Cardiology Blurs Into DTC Retail Health
Statin therapy has been used for decades to lower cholesterol with the goal of reducing mortality and preventing cardiovascular problems such as heart attacks and strokes. Hims & Hers announced a new service offering for health consumers and clinicians concerned about heart health called Heart Health by Hims. This is Hims & Hers’ first foray into cardiovascular health, working in collaboration with the American College of Cardiology (ACC). ACC clinical guidelines will inform the Hims’ provider platform for the program. “Prevention is the ideal mechanism to decrease cardiovascular events and ensure optimal heart
Interviewed live on BNN Bloomberg (Canada) on the market for GLP-1 drugs for weight loss and their impact on both the health care system and consumer goods and services -- notably, food, nutrition, retail health, gyms, and other sectors.
Thank you, Feedspot, for citing the Health Populi blog as one of the best in the field this year! Very grateful to be among the company of some of my own go-to's such as Everyday Health, NPR Health Shots, Health Affairs, and Kaiser Health News, among others...
As you may know, I have been splitting work- and living-time between the U.S. and the E.U., most recently living in and working from Brussels. In the month of September 2024, I'll be splitting time between London and other parts of the U.K., and Italy where I'll be working with clients on consumer health, self-care and home care focused on food-as-medicine, digital health, business and scenario planning for the future...